Zai Lab (09688): zocilurtatug pelitecan demonstrates high response rates, encouraging durability, and a well-tolerated safety profile in first-line extensive-stage small cell lung cancer

Zhitong Finance APP News, Zai Lab (09688) announced that today it released the first data from a global Phase 1b clinical study evaluating zocilurtatug pelitecan (zoci, formerly known as ZL-1310) in combination with atezolizumab (with or without carboplatin) for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). The data will be presented at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.